TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3599344

Group type: EXPERIMENTAL
Intervention: 15 mg chlorthalidone
Number of subjects: 222

Group type: COMPARATOR
Intervention: 25 mg chlorthalidone
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 30904934

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 61

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 61
Study: 29473960

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT)
Number of subjects: 128
Study: 27198187

Group type: COMPARATOR
Intervention: High mycoprotein (132 g)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Medium mycoprotein (88 g)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low mycoprotein (44 g)
Number of subjects: 55
Study: 24515510

Group type: EXPERIMENTAL
Intervention: 800 IU of daily oral vitamin D3
Number of subjects: 48

Group type: COMPARATOR
Intervention: 400 IU of daily oral vitamin D3
Number of subjects: 48
Study: 22931552

Group type: EXPERIMENTAL
Intervention: Delorme's procedure
Number of subjects: 130

Group type: COMPARATOR
Intervention: Resection rectopexy
Number of subjects: 130
Study: 20870000

Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioral therapy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 144
Study: 16574200

Group type: COMPARATOR
Intervention: FXIII subunit A (FXIIIA) levels in sepsis patients (n=40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: FXIII cross‐linking activity (FXIIICA) levels in sepsis patients (n=40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Specific activity of FXIII (SA(FXIII)) in sepsis patients (n=40)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Specific activity of FXIII (SA(FXIII)) in non-survivors vs survivors
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Specific activity of FXIII (SA(FXIII)) in septic shock vs severe sepsis
Number of subjects: 40
Study: 16266408

Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANNs)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 238
Study: 12010112

Group type: EXPERIMENTAL
Intervention: Low family support
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Infrequent mother‐daughter communication
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Mother‐daughter communication about preventing acquired immune deficiency syndrome
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Low perceived family support
Number of subjects: 170

Group type: COMPARATOR
Intervention: Perceived access or financial issues
Number of subjects: 170
Study: 10385714

Group type: EXPERIMENTAL
Intervention: Endoscopic scleroligation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation
Number of subjects: 51
Study: 8681488

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG-modified interferon alfa-2a
Number of subjects: 0
Study: 1810260

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.d.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine and Theophylline (500 mg b.d.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo and Theophylline (500 mg b.d.)
Number of subjects: 8
Study: 6194037

Group type: EXPERIMENTAL
Intervention: Intralipid 5%, 10%, and 20% intravenously for 1 hour with secretin (8.2 pmol . kg‐1 . h‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intralipid 5%, 10%, and 20% intravenously without secretin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intralipid 5%, 10%, and 20% perfused into the intestine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20% Intralipid by intestinal infusion for 2 hours while 10% Intralipid was infused intravenously during the second hour
Number of subjects: 6
Study: 30758406

Group type: EXPERIMENTAL
Intervention: SCTG+CAF+EMD application
Number of subjects: 38

Group type: COMPARATOR
Intervention: SCTG+CAF
Number of subjects: 38
Study: 28577362

Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels
Number of subjects: 12966

Group type: EXPERIMENTAL
Intervention: Highest uric acid quartile
Number of subjects: 12966

Group type: EXPERIMENTAL
Intervention: Hyperuricemia group
Number of subjects: 12966

Group type: EXPERIMENTAL
Intervention: Every 1 mg/dl increase in uric acid concentration
Number of subjects: 12966
Study: 27037729

Group type: EXPERIMENTAL
Intervention: Moist wound healing dressings
Number of subjects: 95

Group type: COMPARATOR
Intervention: Gauze
Number of subjects: 95
Study: 24438620

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS)
Number of subjects: 50
Study: 22019891

Group type: EXPERIMENTAL
Intervention: BBR+CPA
Number of subjects: 89

Group type: COMPARATOR
Intervention: MET+CPA
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo+CPA
Number of subjects: 89
Study: 19581546

Group type: EXPERIMENTAL
Intervention: Healthier advergame condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Less healthy advergame condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study: 17264107

Group type: EXPERIMENTAL
Intervention: Maximum tolerable energy density
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Fixed energy density
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 49
Study: 15118280

Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg daily)
Number of subjects: 212

Group type: COMPARATOR
Intervention: No antiplatelet agent or anticoagulant
Number of subjects: 212

Group type: COMPARATOR
Intervention: Sinus rhythm subjects (control group)
Number of subjects: 212
Study: 11071827

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 2208

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2208
Study: 9382660

Group type: EXPERIMENTAL
Intervention: EDTU care (inhaled adrenergic agonists and steroids for up to 9 hours)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: EDTU care
Number of subjects: 222

Group type: COMPARATOR
Intervention: Inpatient care (routine therapy in a hospital ward)
Number of subjects: 222
Study: 8104738

Group type: EXPERIMENTAL
Intervention: Nonselective beta-blocker propranolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Beta 1-selective blocker metoprolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control patients without CHF
Number of subjects: 24
Study: 3956111

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Immobilization
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Maximal exercise post-immobilization
Number of subjects: 15

Group type: COMPARATOR
Intervention: Maximal exercise post-control
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Maximal exercise post-training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Post-training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Post-immobilization
Number of subjects: 15
Study: 3343502

Group type: EXPERIMENTAL
Intervention: Preconnected urinary catheter drainage system
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard urinary catheter drainage system
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 202
Study: 31831094

Group type: EXPERIMENTAL
Intervention: Consumption of Fe-rich or Fe-fortified foods during 6-23 months of age
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Initial consumption of cows'/goats' milk at 10-12 months
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Initial consumption of high protein-based food at 7-9 months
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Composite infant feeding index in the highest tertile of overall feeding quality
Number of subjects: 745
Study: 30753467

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study: 27730462

Group type: EXPERIMENTAL
Intervention: SAGB
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: MiniMizer Extra
Number of subjects: 103
Study: 26364181

Group type: EXPERIMENTAL
Intervention: Bevacizumab every 3 weeks
Number of subjects: 27
Study: 24490152

Group type: EXPERIMENTAL
Intervention: High-intensity elastic resistance training for 2 minutes per day (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control receiving weekly email-based information on general health (n = 15)
Number of subjects: 30
Study: 21633285

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir-based therapy
Number of subjects: 255

Group type: COMPARATOR
Intervention: Switch to nevirapine-based regimen
Number of subjects: 255
Study: 18326960

Group type: EXPERIMENTAL
Intervention: Irbesartan (ARB) monotherapy at maximal dose
Number of subjects: 81
Study: 17132971

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg b.i.d.; n=203)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo (n=201)
Number of subjects: 404
Study: 14585866

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10699097

Group type: EXPERIMENTAL
Intervention: Early low-dose indomethacin therapy
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 9316359

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 300
Study: 8450099

Group type: EXPERIMENTAL
Intervention: Immediate cognitive-behavior therapy (8-week group intervention)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Delayed cognitive-behavior therapy (8-week group intervention)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 24
Study: 3512025

Group type: EXPERIMENTAL
Intervention: C. parvum, 2 mg/m2 IV, repeated eight times at three weekly intervals
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no C. parvum treatment)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: C. parvum
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 31672172

Group type: EXPERIMENTAL
Intervention: Resistance training and green tea extract (GR, n=8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training (R, n=8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Green tea (G, n=7)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C, n=7)
Number of subjects: 30
Study: 28768544

Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic titanium clip placement
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (palpitation of nodules or esophageal wall mucosal thickening)
Number of subjects: 27
Study: 26234063

Group type: EXPERIMENTAL
Intervention: Side-to-end anastomosis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 80
Study: 23959902

Group type: EXPERIMENTAL
Intervention: Silent video recordings of live music performances
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sound recordings of music performances
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recordings with both video and sound
Number of subjects: 0
Study: 21361732

Group type: EXPERIMENTAL
Intervention: O2A2 group (omeprazole 20 mg twice/day plus amoxicillin 500 mg 4 times/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: O2A1 group (omeprazole 20 mg twice/day plus amoxicillin 250 mg 4 times/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: O1A2 group (omeprazole 20 mg once/day plus amoxicillin 500 mg 4 times/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: O1A1 group (omeprazole 20 mg once/day plus amoxicillin 250 mg 4 times/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Higher dose groups (omeprazole higher dose)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CYP2C19 extensive metabolizers
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Subsequent antibiotic susceptibility‐driven proton pump inhibitor‐based triple therapy
Number of subjects: 128
Study: 18675870

Group type: EXPERIMENTAL
Intervention: DTaP-IPV(Vero)
Number of subjects: 817

Group type: COMPARATOR
Intervention: DTaP-IPV(Mkc)
Number of subjects: 817
Study: 17182505

Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 0
Study: 12660485

Group type: EXPERIMENTAL
Intervention: Combined deep sclerectomy and phacoemulsification (PDS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Deep sclerectomy with implant (DS)
Number of subjects: 42
Study: 10981569

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg every 8 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9503938

Group type: EXPERIMENTAL
Intervention: Superoxide inhalation (15-minute sessions)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Superoxide inhalation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8408980

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both MAOIs
Number of subjects: 39
Study: 3518787

Group type: EXPERIMENTAL
Intervention: Glycerol‐impregnated chromic catgut
Number of subjects: 737

Group type: COMPARATOR
Intervention: Untreated chromic catgut
Number of subjects: 737
Study: 29114041

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 58

Group type: COMPARATOR
Intervention: Antiproteinuric therapy alone
Number of subjects: 58
Study: 27519593

Group type: EXPERIMENTAL
Intervention: Ultra E.R.A.S.
Number of subjects: 765

Group type: COMPARATOR
Intervention: Classic E.R.A.S.
Number of subjects: 765
Study: 26256140

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program over 10 weeks
Number of subjects: 42
Study: 23777506

Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg with each meal for 1 week
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no anti-diabetic agent for 1 week)
Number of subjects: 54
Study: 20620320

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (ceftriaxone and metronidazole, once daily for a minimum of 5 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Oral antibiotics (amoxicillin/clavulanate, after tolerating a regular diet for 7 days)
Number of subjects: 102
Study: 19128668

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 20
Study: 16644316

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (81 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard aspirin (81 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Optical aggregometry with arachidonic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Optical aggregometry with adenosine diphosphate
Number of subjects: 50
Study: 12802741

Group type: EXPERIMENTAL
Intervention: molsidomine 3 x 8 mg t.i.d. for 6 months
Number of subjects: 166

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: molsidomine
Number of subjects: 166
Study: 10780937

Group type: EXPERIMENTAL
Intervention: Enteral Glutamine (0.5 g x kg(‐1) x day(‐1) for 2 days)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Isonitrogenous Ala‐Gly
Number of subjects: 4
Study: 8809523

Group type: EXPERIMENTAL
Intervention: High intensity knee extensor strength training
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 11
Study: 1652611

Group type: EXPERIMENTAL
Intervention: Dronabinol 10 mg every 6 hr plus placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus prochlorperazine 10 mg every 6 hr
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dronabinol and prochlorperazine, each 10 mg every 6 hr
Number of subjects: 0
Study: 6808550

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31818266

Group type: EXPERIMENTAL
Intervention: Routine dialysis initiation at eGFR 7 ml/min/1.73 m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred dialysis initiation at eGFR 5 ml/min/1.73 m2 or less
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine dialysis initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred dialysis initiation
Number of subjects: 0
Study: 27893880

Group type: EXPERIMENTAL
Intervention: Strong African American Families program
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 119
Study: 26545541

Group type: EXPERIMENTAL
Intervention: Stretching program performed once a week for eight weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Stretching program performed twice a week for eight weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no stretching program)
Number of subjects: 180
Study: 24267238

Group type: EXPERIMENTAL
Intervention: ABT-335 (fenofibric acid)
Number of subjects: 0
Study: 21526923

Group type: EXPERIMENTAL
Intervention: Bevacizumab administered monthly
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Ranibizumab administered monthly
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Bevacizumab administered as needed
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Ranibizumab administered as needed
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 1208
Study: 19525191

Group type: EXPERIMENTAL
Intervention: Yttrium‐90 ibritumomab tiuxetan
Number of subjects: 41

Group type: COMPARATOR
Intervention: Short-course rituximab/chemotherapy
Number of subjects: 41
Study: 16458976

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 103
Study: 15673996

Group type: EXPERIMENTAL
Intervention: One tablet of standardized turmeric extract taken daily for 8 weeks
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Two tablets of standardized turmeric extract taken daily for 8 weeks
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 207
Study: 11350464

Group type: EXPERIMENTAL
Intervention: Neostigmine 500 microg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline 1 mL
Number of subjects: 34
Study: 9451487

Group type: EXPERIMENTAL
Intervention: (S)-ketamine/midazolam
Number of subjects: 41

Group type: COMPARATOR
Intervention: racemic ketamine/midazolam
Number of subjects: 41
Study: 8623820

Group type: EXPERIMENTAL
Intervention: Methotrexate and misoprostol
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Other subjects (not complete abortion)
Number of subjects: 86
Study: 2266674

Group type: EXPERIMENTAL
Intervention: L-carnitine (20 mg/kg) post-dialysis for up to six months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 82
Study: 7008244

Group type: EXPERIMENTAL
Intervention: F.X group (anticoagulant dosage based on F.X)
Number of subjects: 42

Group type: COMPARATOR
Intervention: PT group (anticoagulant dosage according to PT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (PT and F.X)
Number of subjects: 42
Study: 30896226

Group type: EXPERIMENTAL
Intervention: PAX GBG Alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PAX GBG + PATHS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard setting (control)
Number of subjects: 27
Study: 28410419

Group type: EXPERIMENTAL
Intervention: ST analysis during labor
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Initial T/QRS baseline
Number of subjects: 1097
Study: 26669548

Group type: EXPERIMENTAL
Intervention: Roughened surface implants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Machined/turned surface implants
Number of subjects: 50
Study: 24961193

Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 540
Study: 22739141

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH; 150 U/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium (1 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (120 IU/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adomiparin sodium (125 IU/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All heparin treatments
Number of subjects: 48
Study: 19846798

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg/day)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 17346654

Group type: EXPERIMENTAL
Intervention: Web-based food portion training program (CFPT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (participants estimating portion sizes before CFPT training)
Number of subjects: 76
Study: 15987460

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (HT)
Number of subjects: 4155

Group type: COMPARATOR
Intervention: Nonusers of HT (Control)
Number of subjects: 4155
Study: 12233878

Group type: EXPERIMENTAL
Intervention: Initial functional status (measured by Health Assessment Questionnaire (HAQ) score)
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Declining HAQ score
Number of subjects: 1269

Group type: COMPARATOR
Intervention: No change or improvement in HAQ score
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Comparison to US population
Number of subjects: 1269
Study: 9001416

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) plus cytosine arabinoside (ara‐C)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Aclarubicin (ACR) plus cytosine arabinoside (ara‐C)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Complete remission after one or two induction courses
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Secondary neoplasms diagnosed simultaneously with or after AML diagnosis
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Patients alive and in complete remission 5 years after AML diagnosis
Number of subjects: 174
Study: 8510086

Group type: EXPERIMENTAL
Intervention: Nicardipine 20-40 mg three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25-100 mg four times daily
Number of subjects: 0